Syndax Pharmaceuticals's Earnings: A Preview
Analysts are estimating that Syndax Pharmaceuticals will report an earnings per share (EPS) of $-1.11. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...
Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Pharmaceutical Technology on MSN20h
Syndax agrees funding with Royalty Pharma for Niktimvo US salesSyndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.
Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial ...
Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $84.1 million in its third quarter. The Waltham, Massachusetts-based company said it had ...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback